Stock Events

Stock Events

Spyre Therapeutics 

$88.98
51
+$1.73+1.98% 20:00 Today
+$0.00+0%21:22After hours

Statistics

Day High
89.18
Day Low
84.68
52W High
110.18
52W Low
14.51
Volume
776,149
Avg. Volume
1,322,509
Mkt Cap
7.85B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.99
-0.71
-0.43
-0.15
Expected EPS
-0.759838
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-155.2MNet Income

Analyst Ratings

107.92Average Price Target
The highest estimate is 130.00.
From 14 ratings within the last 6 months. This is not an investment recommendation.
Buy
93%
Hold
7%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SYRE. It's not an investment recommendation.
Apple
9
AAPL
NVIDIA
9
NVDA
Intel
9
INTC
Lilly(Eli) &
8
LLY

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals focuses on developing treatments for cystic fibrosis and other serious diseases, directly competing in some of the same therapeutic areas as Spyre Therapeutics.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is a biopharmaceutical company that develops and markets drugs in areas such as viral diseases, inflammatory and fibrotic diseases, which overlaps with Spyre Therapeutics' focus areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals is known for its innovations in biotechnology, including treatments for rare diseases, which competes with Spyre Therapeutics' efforts in novel therapeutics.
AMGEN
AMGN
Mkt Cap233.78B
Amgen develops biologic therapies, focusing on oncology and cardiovascular diseases, competing with Spyre Therapeutics in the biopharmaceutical sector.
Biogen
BIIB
Mkt Cap32.28B
Biogen focuses on neurological diseases and innovative therapies, which might overlap with Spyre Therapeutics' research and development in similar therapeutic areas.
Incyte
INCY
Mkt Cap25.21B
Incyte Corporation works on small molecule drugs for oncology and inflammation, competing with Spyre Therapeutics in these crucial healthcare segments.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals develops RNAi therapeutics, a novel approach that could be in direct competition with Spyre Therapeutics' innovative drug development strategies.
Exelixis
EXEL
Mkt Cap13.49B
Exelixis is involved in the discovery, development, and commercialization of new cancer treatments, potentially competing with Spyre Therapeutics in the oncology sector.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and rare genetic diseases treatments, areas that might intersect with Spyre Therapeutics' interests.

About

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Show more...
CEO
Cameron Turtle
Employees
112
Country
United States
ISIN
US00773J2024
WKN
000A3D4LY

Listings

STU
DE
3920.STU
XNAS
US
SYRE
F
DE
3920.F
BOATS
BOATS
SYRE.BOATS

0 Comments

Share your thoughts

FAQ

What is Spyre Therapeutics stock price today?▼
The current price of SYRE is $88.98 USD — it has increased by +1.98% in the past 24 hours. Watch Spyre Therapeutics stock price performance more closely on the chart.
What is Spyre Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Spyre Therapeutics stocks are traded under the ticker SYRE.
Is Spyre Therapeutics stock price growing?▼
SYRE stock has fallen by -1.53% compared to the previous week, the month change is a -15.21% fall, over the last year Spyre Therapeutics has showed a +423.72% increase.
What is Spyre Therapeutics market cap?▼
Today Spyre Therapeutics has the market capitalization of 7.85B
When is the next Spyre Therapeutics earnings date?▼
Spyre Therapeutics is going to release the next earnings report on November 05, 2026.
What were Spyre Therapeutics earnings last quarter?▼
SYRE earnings for the last quarter are -0.36 USD per share, whereas the estimation was -0.76 USD resulting in a +52.56% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Spyre Therapeutics revenue for the last year?▼
Spyre Therapeutics revenue for the last year amounts to 0 USD.
What is Spyre Therapeutics net income for the last year?▼
SYRE net income for the last year is -155.2M USD.
How many employees does Spyre Therapeutics have?▼
As of September 04, 2026, the company has 112 employees.
In which sector is Spyre Therapeutics located?▼
Spyre Therapeutics operates in the Health & Wellness sector.
When did Spyre Therapeutics complete a stock split?▼
The last stock split for Spyre Therapeutics was on September 08, 2023 with a ratio of 1:25.
Where is Spyre Therapeutics headquartered?▼
Spyre Therapeutics is headquartered in WALTHAM, United States.